Kuehn Law Encourages DSKE, RYZB, ROVR, and GRPH Investors to Contact Law Firm
02 févr. 2024 11h58 HE
|
KUEHN LAW, PLLC
Kuehn Law investigates DSKE, RYZB, ROVR, GRPH mergers for shareholder rights, seeking fair process and disclosures.
STOCKHOLDER ALERT: The M&A Class Action Firm Continues Investigating the Merger – AMAM, CSTR, RYZB, THRX
24 janv. 2024 17h16 HE
|
Monteverde & Associates PC
NEW YORK, Jan. 24, 2024 (GLOBE NEWSWIRE) -- Juan Monteverde, founder and managing partner of the class action firm Monteverde & Associates PC (the “M&A Class Action Firm”), a national...
SHAREHOLDER ALERT: The M&A Class Action Firm Continues Investigating the Merger – RYZB, THRX, AMAM, CSTR
19 janv. 2024 20h00 HE
|
Monteverde & Associates PC
NEW YORK, Jan. 19, 2024 (GLOBE NEWSWIRE) -- Juan Monteverde, founder and managing partner of the class action firm Monteverde & Associates PC (the “M&A Class Action Firm”), a national...
STOCKHOLDER ALERT: Juan Monteverde Encourages the Shareholders of HARP, VIA, RYZB, FGH to Take Action
09 janv. 2024 17h36 HE
|
Monteverde & Associates PC
NEW YORK, Jan. 09, 2024 (GLOBE NEWSWIRE) -- Juan Monteverde, founder and managing partner of the class action firm Monteverde & Associates PC (the “M&A Class Action Firm”), a national...
SHAREHOLDER ALERT: Juan Monteverde Encourages the Shareholders of GRCL, RYZB, CVLY, WAVD to Take Action
04 janv. 2024 20h00 HE
|
Monteverde & Associates PC
NEW YORK, Jan. 04, 2024 (GLOBE NEWSWIRE) -- Juan Monteverde, founder and managing partner of the class action firm Monteverde & Associates PC (the “M&A Class Action Firm”), a national...
ALERT: Juan Monteverde Encourages the Shareholders of RYZB, GRCL, X, PGTI to Take Action
26 déc. 2023 18h01 HE
|
Monteverde & Associates PC
NEW YORK, Dec. 26, 2023 (GLOBE NEWSWIRE) -- Juan Monteverde, founder and managing partner of the class action firm Monteverde & Associates PC (the “M&A Class Action Firm”), a national...
RYZB News: Johnson Fistel Investigates Proposed Sale of RayzeBio; Is $62.50 a Fair Price?
26 déc. 2023 09h23 HE
|
Johnson Fistel, LLP
On December 26, 2023, RayzeBio announced that it had entered a deal with Bristol Myers Squibb.
Bristol Myers Squibb Adds Premier Radiopharmaceutical Platform with Acquisition of RayzeBio
26 déc. 2023 07h13 HE
|
Rayzebio, Inc.
Transaction Brings RayzeBio’s Differentiated Actinium-Based Radiopharmaceutical Platform, Including Rich Pipeline of Multiple Drug Development Programs to Bristol Myers Squibb’s Leading Oncology...
RayzeBio Appoints Industry Leader Tim Van Hauwermeiren to Its Board of Directors
01 nov. 2023 06h00 HE
|
Rayzebio, Inc.
SAN DIEGO, Nov. 01, 2023 (GLOBE NEWSWIRE) -- RayzeBio, Inc. (Nasdaq: RYZB), a targeted radiopharmaceutical company developing an innovative pipeline against validated solid tumor targets, today...